In the protracted war between humanity and cancer, the concept of precision medicine is leading a profound transformation. Scientists are no longer satisfied with the traditional therapy of "killing one thousand enemies and self harming eight hundred", but are committed to developing "smart bombs" that can accurately identify and destroy cancer cells while maximizing the protection of healthy tissues. In this cutting-edge field, the radioactive isotope terbium-161 (¹⁶¹ Tb) is rising to become a highly anticipated "medical nuclear warhead" due to its unique physical properties and therapeutic potential. And its birth cannot be separated from its stable and crucial 'parent' - gadolinium-160 (¹⁶⁰ Gd).

1. Gadolinium-160: Transformation from stable element to key precursor
Gadolinium (Gd), the 64th element in the periodic table, belongs to rare earth metals. In daily life, we may feel unfamiliar with it, but in the field of medical imaging, its compounds have long been an indispensable contrast agent component in magnetic resonance imaging (MRI), helping doctors gain clear insights into the internal structure of the human body. However, the specific isotope of gadolinium, gadolinium-160, has a more special mission.
Gadolinium-160 itself is a relatively rare but stable isotope with no radioactivity. Its magic lies in its atomic nucleus structure - it is an ideal 'target'. When high-purity gadolinium-160 is placed in a specially designed nuclear reactor and subjected to the "baptism" of high-throughput neutrons, a wonderful nuclear transformation begins. The nucleus of gadolinium-160 captures a neutron and transforms into the radioactive isotope gadolinium-161 (¹⁶¹ Gd). This process is called 'neutron activation'.
The lifecycle of ¹⁶¹ Gd is very short, with a half-life of only 3.66 minutes. It will rapidly undergo beta decay (releasing an electron and an antineutrino) to transform into the desired target - terbium-161 (¹⁶¹ Tb). This production process requires extremely high purity of the raw material gadolinium-160, as any impurities may produce other unwanted radioactive isotopes under neutron irradiation, affecting the purity and specific activity (radioactivity per unit mass) of the final product terbium-161.
Therefore, obtaining high abundance gadolinium-160 and performing precise purification and separation is a crucial link in the entire production chain. It can be said that gadolinium-160, with its stable and easily convertible properties, paved the way for the large-scale production of terbium-161 and is truly the cornerstone.

2. Terbium 161: a "diagnosis and treatment integrated" star that combines diagnosis and treatment
The reason why terbium-161 stands out among many medical radioactive isotopes is mainly due to its almost perfect decay characteristics, which make it not only a powerful therapeutic tool, but also has the potential for diagnostic imaging, perfectly fitting the "Theranos" concept of modern nuclear medicine development.
β ⁻ particles - the main output, destroying the tumor body:
The half-life of terbium-161 is 6.89 days, which is an ideal treatment window that ensures sufficient time for the drug to take effect after targeting the tumor, without unnecessary long-term radiation exposure due to a long half-life. The average energy of the beta ⁻ particles released during its decay is about 154 keV, with a maximum energy of 593 keV. These beta ⁻ particles act like cruise missiles, able to travel several millimeters through tissues and effectively 'sweep' larger tumor clusters, disrupting the DNA strands of cancer cells and inducing their apoptosis. This is similar to the widely used lutetium 177 (¹⁷⁷ Lu) in clinical practice, which is also an excellent beta emitter.
Auger electrons and conversion electrons - microscopic sharp blades, clearing residual lesions:
This is the true 'trump card' of terbium-161. In addition to beta ⁻ particles, terbium-161 also releases a large number of low-energy Auger electrons and conversion electrons during its decay process. Although the energy of these electrons is not high (mainly concentrated below the keV level), their linearly endowed energy (LET) is very high, which means they can densely transfer energy to cellular structures, especially DNA in the nucleus, over extremely short distances (nanometer to micrometer level). This high LET radiation causes more complex and fatal damage to DNA, such as causing irreparable DNA double strand breaks.
The unique value of Auger electrons: Due to their extremely short range, even shorter than the diameter of a single cell, Auger electrons can achieve precise "cell level" killing once released inside or adjacent to the surface of cancer cells. This has incomparable advantages in clearing isolated cancer cells, small clusters of cancer cells (i.e. micro metastases), and tumor stem cells that are resistant to traditional radiotherapy. These micro metastatic lesions are often the root cause of cancer recurrence and spread, which are difficult to detect through conventional imaging examinations and cannot be eradicated by traditional treatment methods. The Auger electrons of terbium-161 provide new hope for solving this problem.
Gamma rays - real-time tracking for visualized treatment:
During decay, terbium-161 also emits specific energies of gamma rays (mainly 25.6 keV, 48.9 keV, 74.6 keV, etc.), which can be detected by SPECT (single photon emission computed tomography) equipment. This means that doctors can perform real-time imaging and quantitative evaluation of the distribution of terbium-161 labeled drugs in the body, tumor uptake, and drug clearance rate during the treatment process. This' visible treatment 'enables doctors to more accurately optimize dosage, predict treatment response, and adjust treatment plans in a timely manner, truly achieving personalized and precise treatment. Lutetium-177 also emits gamma rays that can be used for SPECT imaging, but the superior electron spectrum provided by terbium-161 makes it more attractive in terms of therapeutic efficacy.

3. Comparison with Lutetium-177: Is blue better than blue?
Lutetium-177 (¹⁷⁷ Lu) is currently one of the most successful isotopes used in radioligand therapy (RLT), with significant achievements in the treatment of neuroendocrine tumors and prostate cancer. Terbium 161 and lutetium 177 have very similar chemical properties, which means that many targeted molecules (such as peptides and antibodies) already developed for lutetium 177 can be relatively easily adapted for use with terbium-161.
However, research suggests that terbium-161 may have some theoretical advantages over lutetium 177:
Stronger cell killing efficacy: Terbium 161 releases significantly more converted electrons and Auger electrons than lutetium 177, especially in the low-energy range. This makes terbium-161 potentially more potent at the cellular level, especially against small-sized tumors or individual cancer cells.
Potential better control of micro transfer foci: It is precisely due to the presence of these short-range high-energy electrons that terbium-161 is highly expected to control and eliminate micro transfers, which may be the key to its surpassing lutetium 177.
Of course, more clinical data is needed to confirm these theoretical advantages.

4. Application exploration in the forefront of tumor treatment
The therapeutic potential of terbium-161 is being actively explored in multiple types of cancer, with the most notable being prostate cancer and neuroendocrine tumors.
A new weapon for prostate cancer - ¹⁶¹ Tb PSMA:
Prostate cancer is a common malignant tumor in men. A protein called prostate-specific membrane antigen (PSMA) is highly expressed on the surface of the vast majority of prostate cancer cells, especially metastatic and castration resistant prostate cancer cells, while its expression level is very low in normal tissues. This makes it an ideal therapeutic target. Scientists have developed ¹⁶¹ Tb PSMA radiopharmaceuticals by combining terbium-161 with small molecule ligands that can specifically bind to PSMA, such as PSMA-617 or PSMA-I&T. Preclinical studies and preliminary clinical trial data show that ¹⁶¹ Tb PSMA has demonstrated encouraging results in effectively killing tumor cells and reducing tumor volume, and is expected to provide a new lifeline for advanced prostate cancer patients.
Precise Sniper for Neuroendocrine Tumors - ¹⁶¹ Tb DOTATOC/DOTATATE:
Neuroendocrine tumors (NETs) are a type of heterogeneous tumor originating from neuroendocrine cells and can occur in multiple parts of the body. Many NETs cells have high expression of somatostatin receptor (SSTR) on their surface. By utilizing this property, terbium-161 can be coupled with somatostatin analogs (such as DOTATOC or DOTATATE) to form ¹⁶¹ Tb SSTR analog radiopharmaceuticals. This drug can precisely target and destroy NETs cells like a "biological missile". Considering the potential of terbium-161 in killing small lesions, it may be particularly effective in controlling the widespread metastasis of NETs.

5. Challenges and future prospects: The path to light
Despite the bright prospects of terbium-161, there are still some challenges to overcome on its path towards widespread clinical applications:
Large scale and standardized production: Although the production path has been clearly defined, in order to meet potential clinical needs in the future, it is necessary to further optimize the enrichment technology of gadolinium-160, improve neutron irradiation efficiency, and establish a terbium-161 production and purification process that complies with Good Manufacturing Practice (GMP) to ensure stable supply and high quality.
Accurate assessment of dosimetry: The range of Auger electrons and converted electrons is extremely short, and their energy deposition is highly uneven, which poses a challenge for accurately calculating the absorbed dose of cells and tissues. More precise microdosimetry models and measurement techniques need to be developed to better understand their biological effects and guide clinical medication.
In depth validation of clinical trials: Although early research results are exciting, large-scale, multicenter, randomized controlled phase III clinical trials are still needed to ultimately confirm the efficacy and safety of terbium-161 labeled drugs in different types of cancer, and to clarify their optimal positioning in the treatment pathway.
Exploration of Combination Therapy: In the future, terbium-161 radioligand therapy is likely to be used in combination with other treatment methods such as immunotherapy, chemotherapy, targeted drug therapy, etc., in order to achieve synergistic effects, further improve treatment efficacy, and overcome drug resistance.